Kernal Biologics has been awarded up to $48 million in funding to accelerate the development of KR-402, a next-generation CAR T-cell therapy for multiple sclerosis (MS) and certain blood cancers.

Kernal Biologics Inc, a venture-backed TechBio company pioneering novel therapeutics to programme human cells directly inside the body, announced that it has been awarded up to $48 million in funding ...

NEW YORK – Kernal Biologics on Tuesday said the Advanced Research Projects Agency for Health (ARPA-H) awarded the company up to $48 million to support development of its in vivo mRNA-encoded CAR ...

Kernal Biologics, Inc., a venture-backed TechBio company pioneering novel therapeutics to program human cells directly inside the body, today announced that it has been awarded up to $48 million in ...

The U.S. government has awarded Kernal Bio and three other sub-awardees up to $48 million to help advance the biotech’s in vivo mRNA-encoded CAR T-cell program. In an interesting—if not somewhat ...

BOSTON--(BUSINESS WIRE)--Kernal Biologics, Inc., a venture-backed therapeutics company developing novel therapeutics to program human cells directly inside the body, today announced its relocation to ...

Kernal Biologics, Inc., a venture-backed therapeutics company developing novel therapeutics to program human cells directly inside the body, today announced its relocation to Lilly Gateway Labs (LGL) ...

BOSTON, October 03, 2025--(BUSINESS WIRE)--Kernal Biologics, Inc., a venture-backed therapeutics company developing novel therapeutics to program human cells directly inside the body, today announced ...

Pull requests help you collaborate on code with other people. As pull requests are created, they’ll appear here in a searchable and filterable list. To get started, you should create a pull request.